BioNTech Results Presentation Deck
August 2020, 28 slides
  1. BioNTech
  2. Related Decks
  3. Results Presentation Decks
march second quarter corporate update and financial results august | BioNTech
forward looking statements | BioNTech
next generation harnessing the full potential of the immune system broad suite of novel technology platforms for cancer and infectious diseases fully integrated with in house manufacturing industry leading global collaborations | BioNTech
agenda highlights oncology pipeline update covid vaccine program financial update and outlook | BioNTech
highlights melanoma financings in year to date | BioNTech
we expanded our base of strategic collaborators in to date collaborations for clinical stage programs clinical collaborations royalties indications | BioNTech
broad progress in executing our platform strategy a | BioNTech
agenda highlights oncology pipeline update covid vaccine program financial update and outlook | BioNTech
expanded clinical stage pipeline to product candidates across trials | BioNTech
melanoma planning to initiate randomized phase trial | BioNTech
publication in nature highlights as he ten of anti vaccination | BioNTech
recent data update | BioNTech
randomized phase trials ongoing and planned | BioNTech
next gen | BioNTech
anti anti | BioNTech
initiated phase trial for our agonist in | BioNTech
agenda highlights oncology pipeline update covid vaccine program financial update and outlook | BioNTech
status of covid vaccine program | BioNTech
selected as lead candidate for phase mutated full sarna sing sas gon | BioNTech
rationale for selection of for pivotal phase trial | BioNTech
global phase design | BioNTech
commercial update | BioNTech
commercial update | BioNTech
agenda highlights oncology pipeline update covid vaccine program financial update and outlook | BioNTech
second quarter financial results unaudited profit and loss | BioNTech
second quarter financial results unaudited balance sheet cash and cash equivalents of as of june full year guidance and for the full year offering and the expected net proceeds from the private investment are expected to the next months | BioNTech
outlook for with melanoma update in enrollment | BioNTech
a | BioNTech
See More
BioNTech
Results Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Vaccine
Tumor
Cancer
Melanoma
Solid tumor
Clinical trial
Recent decks by BioNTech
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
See all presentations by BioNTech (12 decks)
Related decks
Erasca
Investor Presentation
November 2023
Erasca
Investor Presentation
August 2023
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
November 2023
Mink Therapeutics
IPO
October 2021
Immatics
Investor Presentation
November 2023
TScan Therapeutics
IPO
July 2021
Enochian Biosciences
Results
August 2023
Recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Erasca
Investor Presentation
November 2023
Erasca
Investor Presentation
August 2023
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
November 2023
Mink Therapeutics
IPO
October 2021
Immatics
Investor Presentation
November 2023
TScan Therapeutics
IPO
July 2021
Enochian Biosciences
Results
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights